News

Vitamin D appears protective in patients with metastatic colorectal cancer

Publish date: January 17, 2015

 

AT THE 2015 GASTROINTESTINAL CANCERS SYMPOSIUM

References

The research was supported by the National Cancer Institute. Dr. Krishnamurthi had no relevant disclosures. Many of Dr. Ng’s coauthors reported financial ties to multiple companies, including Bristol-Myers Squibb, which funded the CALGB 80405 trial.

Pages

Recommended Reading

Identification of subtypes, mutations in CRC and colon cancer greatly increases survival rates
MDedge Hematology and Oncology
Stage, lymph node status should drive gastric cancer treatment decisions
MDedge Hematology and Oncology
Microbiota organization influences colorectal cancers
MDedge Hematology and Oncology
Outcomes of stage III colon cancer appear better for aspirin, COX-2 inhibitor users
MDedge Hematology and Oncology
Skipping surgery is an option for some patients with rectal cancer
MDedge Hematology and Oncology
Ramucirumab may expand treatment options for metastatic colorectal cancer
MDedge Hematology and Oncology
TRIBE update: FOLFOXIRI-bevacizumab boosts survival in metastatic CRC
MDedge Hematology and Oncology
Stage IV CRC survival rates up, resection rates down
MDedge Hematology and Oncology
Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome
MDedge Hematology and Oncology
Rectal cancer management in elderly patients: experience of a single Portuguese institution
MDedge Hematology and Oncology